XKRX
002210
Market cap15mUSD
Jun 24, Last price
973.00KRW
Name
Dongsung Pharmaceutical Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Dong Sung Bio Pharm.Co.,Ltd. is a South Korean company with diverse operations spanning pharmaceuticals, cosmetics, hair dye manufacturing, and photodynamic therapy. Its extensive product range includes a broad selection of over-the-counter (OTC) medications designed to treat a variety of conditions. These encompass liver ailments, menopausal symptoms, skin disorders, obesity, digestive and gum health issues, and hair loss. The company's OTC offerings also feature remedies for fever, pain, inflammation, respiratory illnesses, scar reduction, and sleep disturbances, along with antiviral, anti-diarrhea, anti-nausea, blood circulation enhancing, antifungal, and antihistamine drugs. Supplementary OTC products include keratin softeners, eye nutrition supplements, and essential vitamins. Furthermore, Dong Sung Bio Pharm produces ethical (prescription-only, or ETC) drugs. These target specific medical areas such as endocrine, gastrointestinal, circulatory, neuropsychological, and oncological conditions. Its ETC portfolio also contains analgesic and anti-inflammatory agents, dermato-urinary treatments, antiviral, antibiotic, antifungal, and antihistamine medications, as well as respiratory drugs, steroids, and ophthalmic drops. Beyond its pharmaceutical lines, the company offers a range of consumer health and personal care items. These include hair coloring products, functional health foods, medical devices, various daily necessities, muscle taping supplies, disinfectants, toothpastes, shampoos for anti-hair loss and hair growth, and sanitary pads. Dong Sung Bio Pharm.Co.,Ltd. was founded in 1957 and maintains its headquarters in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||